These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 16360440

  • 1. Frequency and clinicopathologic correlates of ErbB1, ErbB2, and ErbB3 immunoreactivity in urothelial tumors of upper urinary tract.
    Tsai YS, Tzai TS, Chow NH, Wu CL.
    Urology; 2005 Dec; 66(6):1197-202. PubMed ID: 16360440
    [Abstract] [Full Text] [Related]

  • 2. [The expression of p53 and c-erb-2 in transitional cell carcinoma of the kidney pelvis and ureter and its relation to tumor progression and survival].
    Fontana LO, García García F, Arcas Martínez Salas I, García Ligero J, Tomás Ros M, Rico Galiano JL, Sempere Gutiérrez A, Canteras Jordana M.
    Arch Esp Urol; 2002 Sep; 55(7):792-6. PubMed ID: 12380307
    [Abstract] [Full Text] [Related]

  • 3. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder.
    Chow NH, Chan SH, Tzai TS, Ho CL, Liu HS.
    Clin Cancer Res; 2001 Jul; 7(7):1957-62. PubMed ID: 11448910
    [Abstract] [Full Text] [Related]

  • 4. Enhanced drug resistance in cells coexpressing ErbB2 with EGF receptor or ErbB3.
    Chen X, Yeung TK, Wang Z.
    Biochem Biophys Res Commun; 2000 Nov 02; 277(3):757-63. PubMed ID: 11062025
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.
    Spector NL, Xia W, Burris H, Hurwitz H, Dees EC, Dowlati A, O'Neil B, Overmoyer B, Marcom PK, Blackwell KL, Smith DA, Koch KM, Stead A, Mangum S, Ellis MJ, Liu L, Man AK, Bremer TM, Harris J, Bacus S.
    J Clin Oncol; 2005 Apr 10; 23(11):2502-12. PubMed ID: 15684311
    [Abstract] [Full Text] [Related]

  • 10. Expression of cyclooxygenase-2 and EP4 receptor in transitional cell carcinoma of the upper urinary tract.
    Miyata Y, Kanda S, Nomata K, Eguchi J, Kanetake H.
    J Urol; 2005 Jan 10; 173(1):56-60. PubMed ID: 15592025
    [Abstract] [Full Text] [Related]

  • 11. ErbB receptors and fatty acid synthase expression in aggressive head and neck squamous cell carcinomas.
    Silva SD, Cunha IW, Younes RN, Soares FA, Kowalski LP, Graner E.
    Oral Dis; 2010 Nov 10; 16(8):774-80. PubMed ID: 20604875
    [Abstract] [Full Text] [Related]

  • 12. Expression of Ki-67 and COX-2 in patients with upper urinary tract urothelial carcinoma.
    Jeon HG, Jeong IG, Bae J, Lee JW, Won JK, Paik JH, Kim HH, Lee SE, Lee E.
    Urology; 2010 Aug 10; 76(2):513.e7-12. PubMed ID: 20573388
    [Abstract] [Full Text] [Related]

  • 13. Overexpression of hypoxia-inducible factor-1alpha predicts an unfavorable outcome in urothelial carcinoma of the upper urinary tract.
    Ke HL, Wei YC, Yang SF, Li CC, Wu DC, Huang CH, Wu WJ.
    Int J Urol; 2008 Mar 10; 15(3):200-5. PubMed ID: 18304212
    [Abstract] [Full Text] [Related]

  • 14. MUC4 and ERBB2 expression in major and minor salivary gland mucoepidermoid carcinoma.
    Weed DT, Gomez-Fernandez C, Pacheco J, Ruiz J, Hamilton-Nelson K, Arnold DJ, Civantos FJ, Zhang J, Yasin M, Goodwin WJ, Carraway KL.
    Head Neck; 2004 Apr 10; 26(4):353-64. PubMed ID: 15054739
    [Abstract] [Full Text] [Related]

  • 15. Risk factors for intravesical recurrence after surgical management of transitional cell carcinoma of the upper urinary tract.
    Terakawa T, Miyake H, Muramaki M, Takenaka A, Hara I, Fujisawa M.
    Urology; 2008 Jan 10; 71(1):123-7. PubMed ID: 18242379
    [Abstract] [Full Text] [Related]

  • 16. Different patterns of expression of the erbB family of receptor tyrosine kinases in common nevi, dysplastic nevi, and primary malignant melanomas: an immunohistochemical study.
    Feinmesser M, Veltman V, Morgenstern S, Tobar A, Gutman H, Kaganovsky E, Tzabari C, Sulkes J, Okon E.
    Am J Dermatopathol; 2010 Oct 10; 32(7):665-75. PubMed ID: 20559114
    [Abstract] [Full Text] [Related]

  • 17. Clinical significance of lymphovascular invasion in upper urinary tract urothelial cancer.
    Akao J, Matsuyama H, Yamamoto Y, Hara T, Kawai Y, Sakano S, Ohmi C, Gondo T, Naito K.
    BJU Int; 2008 Aug 05; 102(5):572-5. PubMed ID: 18485032
    [Abstract] [Full Text] [Related]

  • 18. Location of the primary tumor is not an independent predictor of cancer specific mortality in patients with upper urinary tract urothelial carcinoma.
    Isbarn H, Jeldres C, Shariat SF, Liberman D, Sun M, Lughezzani G, Widmer H, Arjane P, Pharand D, Fisch M, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI.
    J Urol; 2009 Nov 05; 182(5):2177-81. PubMed ID: 19758662
    [Abstract] [Full Text] [Related]

  • 19. Behavior of urothelial carcinoma with respect to anatomical location.
    Catto JW, Yates DR, Rehman I, Azzouzi AR, Patterson J, Sibony M, Cussenot O, Hamdy FC.
    J Urol; 2007 May 05; 177(5):1715-20. PubMed ID: 17437794
    [Abstract] [Full Text] [Related]

  • 20. Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors.
    Zhan L, Xiang B, Muthuswamy SK.
    Cancer Res; 2006 May 15; 66(10):5201-8. PubMed ID: 16707444
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.